US Patent Issued to STAIDSON (BEIJING) BIOPHARMACEUTICALS on Jan. 27 for "Antibodies specifically recognizing C5A and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,521, issued on Jan. 27, was assigned to STAIDSON (BEIJING) BIOPHARMACEUTICALS Co. LTD. (Beijing).

"Antibodies specifically recognizing C5A and uses thereof" was invented by Pingxia Zhu (Beijing) and Zhong Li (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides antibodies including antigen-binding fragments thereof that specifically recognizing Complement component 5a (C5a). Also provided are methods of making and using these antibodies."

The patent was filed on June 18, 2021, under Application No. 18/012,580.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/neta...